Pulse Biosciences, Inc. (PLSE)
| Market Cap | 3.84B +186.1% |
| Revenue (ttm) | 1.19M |
| Net Income | -80.06M |
| EPS | -1.18 |
| Shares Out | 71.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 365,804 |
| Open | 49.98 |
| Previous Close | 49.98 |
| Day's Range | 49.98 - 53.97 |
| 52-Week Range | 12.56 - 58.90 |
| Beta | 1.57 |
| Analysts | Strong Buy |
| Price Target | 56.50 (+5.0%) |
| Est. Earnings | Nov 4, 2026 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled conso... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PLSE stock is "Strong Buy." The 12-month stock price target is $56.5, which is an increase of 5.00% from the latest price.
News
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences' nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technolo...
Pulse Biosciences announces NANOPULSE-AF study met enrollment target
Pulse Biosciences (PLSE) announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. “The enrollment pace reflects the enthusiasm we saw...
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announ...
Pulse Biosciences price target raised to $58 from $43 at Canaccord
Canaccord raised the firm’s price target on Pulse Biosciences (PLSE) to $58 from $43 and keeps a Buy rating on the shares. The firm met with management where they discussed…
Pulse Biosciences management to meet with Oppenheimer
Meeting to be held in San Francisco on October 7-8 hosted by Oppenheimer.
Pulse Biosciences management to meet virtually with Freedom Capital
Virtual Meeting to be held on September 29 hosted by Freedom Capital.
Pulse Biosciences initiated with a Buy at BTIG
BTIG initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $70 price target The company has developed a nanosecond pulsed field ablation technology that operates meaningfully faster tha...
Pulse Biosciences falls -10.6%
Pulse Biosciences (PLSE) is down -10.6%, or -$5.85 to $49.35.
Pulse Biosciences falls -6.2%
Pulse Biosciences (PLSE) is down -6.2%, or -$3.42 to $51.78.
Pulse Biosciences announces two milestones in PRECISE-BTN study
Pulse Biosciences (PLSE) announced two milestones in the PRECISE-BTN clinical study evaluating the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules...
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energ...
Pulse Biosciences rises 19.5%
Pulse Biosciences (PLSE) is up 19.5%, or $9.53 to $58.32.
Pulse Biosciences initiated with a Buy at Freedom Capital
Freedom Capital initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $73 price target The firm says the atrial fibrillation ablation market is large, growing and “disruptable.” Pulse’s...
Pulse Biosciences announces inducement grants under Nasdaq listing rule
Pulse Biosciences (PLSE) announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company’s 2017…
Pulse Biosciences announces inducement grants under Nasdaq listing rule
Pulse Biosciences (PLSE) announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company’s 2017…
Pulse Biosciences initiated with a Buy at Needham
Needham initiated coverage of Pulse Biosciences (PLSE) with a Buy rating and $58 price target The company has developed “differentiated” pulse field ablation platform technology, Nanosecond Pulsed Fie...
Pulse Biosciences management to meet virtually with BTIG
Virtual Meeting to be held on August 14 hosted by BTIG.
Pulse Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
Leadership with deep med tech and VC experience is driving rapid progress in next-generation nsPFA technology, which shows unprecedented efficacy and efficiency in AFib treatment. Strong clinical data, a unique competitive position, and a partnership-focused strategy support broad future applications.
Pulse Biosciences management to meet virtually with BTIG
Virtual Meeting to be held on August 17-18 hosted by BTIG.
Pulse Biosciences price target raised to $43 from $32 at Canaccord
Canaccord raised the firm’s price target on Pulse Biosciences (PLSE) to $43 from $32 and keeps a Buy rating on the shares. The firm said Pulse continues to make clinical-regulatory…
Pulse Biosciences price target raised to $45 from $30 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Pulse Biosciences (PLSE) to $45 from $30 and keeps an Outperform rating on the shares. The firm sees improving success…
Pulse Biosciences Slides: Investor presentation
Pulse Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 7, 2026.
Pulse Biosciences reports Q2 EPS (36c) vs (28c) last year
Reports Q2 revenue $400,000, consensus $533,330. “This was a highly productive quarter for Pulse Biosciences (PLSE), defined by exceptional momentum in our cardiac catheter program,” said Paul LaViole...
Pulse Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 saw rapid clinical trial enrollment, strong physician enthusiasm, and expanded partnerships, with revenue of $434,000 and a strengthened cash position of $101.6 million. Key IDE studies are ahead of schedule, and capital raised supports continued clinical and market development.